Huons BioPharma attracts $132 mil from China's Imeik Technology Development Subsidiary of Huons Global aims to enter Chinese botulinum toxin market
Translated by Kim So-in 공개 2021-09-24 08:09:51
이 기사는 2021년 09월 24일 08:07 thebell 에 표출된 기사입니다.
Huons BioPharma, a subsidiary of Huons Global, has attracted 155.4 billion won ($132 million) from China’s Imeik Technology Development, gaining a foothold in the rapidly botulinum toxin market in China.Huons BioPharma received a total of 155.4 billion won from Imeik Technology Development on September 16 after the two companies signed an agreement in June. Imeik Technology Development, which manufactures and distributes biomedical products, aims to enter the botulinum toxin market there through the latest partnership.
Imeik Technology Development has become the second largest shareholder of Huons BioPharma by securing a 25.4% stake in the Korean company. Huons Global remains to be the largest shareholder, although its stake has been reduced to 74.6%.
Huons Global teamed up with Imeik Technology Development about two months after it established Huons BioPharma through a split-off in April. Huons Global is speeding up its efforts to expand its business in China by completing the deal process within six months.
Huons BioPharma’s botulinum toxin product, Hutox, is currently under preparation to launch phase 3 clinical trials in China.
Huons BioPharma targets the Chinese market through the latest partnership, which has high growth potential and is relatively less competitive. The Chinese botulinum toxin market is expected to reach 2 trillion won by 2025, about four times bigger than that of Korea.
Huons Global and Huons BioPharma expect it will take about three to four years for Hutox to enter the Chinese market after completing phase 3 clinical trials and obtaining approval from the China's National Medical Products Administration (NMPA). Currently in China, botulinum toxin formulations produced by U.S.’ Allergan, Korea’s Hugel, France’s Ipsen, and a Chinese state-run research institute are on the market.
“Considering all circumstances, we will be able to create a three-way battle or better, thanks to product competitiveness, even if we are a late comer to the market,” said an official at Huons Global. “We will actively utilize our partnership with Imeik to ensure that our clinical trials and business operations go smoothly.” (Reporting by Eun-su Choi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- [그것이 '알(리)'고 싶다]알리, 334억 유상증자 '1.5조 투자 시동거나'
- "글로벌 기술력 어필"…모델솔루션 'CMF 오픈하우스'
- LG전자, 러·우 전쟁 장기화에 모스크바연구소 철수
- [엔비디아 밸류체인 파트너]'8년 만에 적자' 브이엠, 해외진출 없이 반등 어렵다
- [한경협 파이낸셜 리포트]'부동산 거부 단체' 시세 1.3조 여의도 전경련회관
- [thebell interview]김경수 팹리스협회장 "한국판 엔비디아가 필요하다"
- LS에코에너지, 1분기 날았다 '모기업과 시너지 본격'
- [모두투어를 움직이는 사람들]'전략가' 조재광 상품본부장, 여행에 '취미' 더했다
- [폰드그룹을 움직이는 사람들]'조율사' 임종민 대표, 균형 잡힌 운영으로 새 판 짠다
- [IB 풍향계]바이오 IPO 보릿고개…업프론트 1400억도 'BBB'